SOUTH SAN FRANCISCO, CA--(Marketwire - June 05, 2008) - Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract summarizing data from a Phase I/II clinical trial evaluating its drug candidate SB-743921 in the treatment of patients with Hodgkin or non-Hodgkin lymphoma was presented at the 10th International Conference on Malignant Lymphoma, at the Palazzo Dei Congressi in Lugano, Switzerland. SB-743921 is a novel, small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division.
